# OnCo record paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015" ;
  schema:name "FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of TRIBE"@en ;
  schema:description "Giving all three chemotherapy drugs at once rather than two added four months of life, and worked whatever the RAS or BRAF status. It is the most intensive first-line option for patients fit enough to take it."@en ;
  schema:url <https://onco.cc/key-papers/paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(15)00122-9>, <https://pubmed.ncbi.nlm.nih.gov/26338525/> ;
  onco:tag "colorectal-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(15)00122-9> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Cremolini C, Loupakis F, Antoniotti C, et al." ;
  onco:related <https://onco.cc/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/>, <https://onco.cc/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/braf-v600e-colorectal/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/fluorouracil/> ;
  onco:terms <https://onco.cc/terms/folfox-family/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .